| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | Biomarker | disease | BEFREE | Furthermore, SCLC patients exhibited a significant decrease in the percentage of circulating PD-1<sup>+</sup> Tfh and Tph cells following chemotherapy, and the in vitro analysis revealed that the concentration of IL-2 and IFN-γ derived from PD-1 + Tfh cells in SCLC were significantly lower than that from NSCLC. | 31381177 | 2019 | ||||
|
0.070 | Biomarker | disease | BEFREE | The recent emergence of immunotherapy treatment options, such as the use of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors, has also led to a paradigm shift in the treatment of non-small cell lung cancer, and has provided promising directions for the treatment of small cell lung cancer. | 30819828 | 2019 | ||||
|
0.070 | Biomarker | disease | BEFREE | Indeed, combinations of cytotoxic chemotherapy and PD-1/PD-L1 inhibitors have been approved and are now used in clinical practice for the treatment of advanced non-small cell lung cancer and small cell lung cancer on the basis of positive results of large-scale clinical trials. | 31549270 | 2019 | ||||
|
0.070 | Biomarker | disease | BEFREE | Recent efforts to expand the therapeutic arsenal toward SCLC have focused in part on immune checkpoint inhibitors, such as agents targeting the receptor-ligand pair programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1). | 29535912 | 2018 | ||||
|
0.070 | Biomarker | disease | BEFREE | Mechanistically, we show that VEGFA enhances coexpression of the inhibitory receptor TIM-3 on T cells, indicating an immunosuppressive function of VEGF in patients with SCLC during anti-PD-1-targeted treatment. | 29776963 | 2018 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | However, data on clinical activity by programmed cell death-1 ligand expression in SCLC are not widely available. | 27520630 | 2017 | ||||
|
0.070 | Biomarker | disease | BEFREE | Of several immunotherapies being investigated, antibodies that target the programmed cell death protein-1 (nivolumab and pembrolizumab) and cytotoxic T-lymphocyte antigen-4 (ipilimumab) immune checkpoint pathways are among the most promising for patients with SCLC and are the focus of this review. | 27354668 | 2016 |